Skip to main content
Erschienen in: International Urology and Nephrology 10/2017

15.06.2017 | Nephrology - Original Paper

Factors affecting responsiveness to hepatitis B immunization in dialysis patients

verfasst von: Ali Asan, Huriye Demirhan, Hülya Çetin Sorkun, Sevgi Özkan, Mehtap Aydın, Davut Akın, Bengü Tatar, Binali Çatak, Alper Şener, Şükran Köse

Erschienen in: International Urology and Nephrology | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are widespread health problems all over the world and have high morbidity and mortality. Hemodialysis patients are more frequently exposed to these viruses as they have poor immune system and frequently undergo parenteral interventions. The vaccination against HBV prevents infection and it has been recommended for the prevention of HBV infection in all susceptible dialysis patients. This study aimed to determine the seroprevalence of HBV and HCV infections and analyzed the factors affecting inadequate response to HBV vaccine in dialysis patients.

Methods

The data for 584 dialysis patients that were followed up at seven dialysis centers were analyzed. The patients received four doses of 40 μg recombinant hepatitis B vaccine at 0, 1, 2, and 6 months and were tested for anti-HBs titer after one month of completion of vaccination. If patients showed a titer of anti-HBs <10 IU/mL, an additional 40 μg in four vaccine doses was administered immediately and they were retested for the anti-HBs following the same schedule. The patients were divided into two groups: responders and non-responders.

Results

HBsAg and anti-HCV seroprevalence was 3.4% and 10.3%, respectively. After vaccination schedule, 264 (83.5%) patients had antibody response to HBV vaccine and 52 (16.5%) had no response. Hepatitis B vaccine unresponsiveness is more common in the patients with hepatitis C positivity (p = 0.011), BMI >30 (p = 0.019), over the age of 65 years (p = 0.009), and duration of dialysis treatment >5 years (p = 0.001). There was no statistically significant difference between gender, causes of renal disease, erythropoietin treatment, and the type of dialysis.

Conclusion

Hepatitis C infection, obesity, being elderly, and having long hemodialysis period reduced the hepatitis B vaccination response in hemodialysis patients.
Literatur
4.
Zurück zum Zitat Cheng CH, Huang CC, Leu ML et al (1997) Hepatitis B vaccine in hemodialysis patients with hepatitis C infection. Vaccine 15:1353–1357CrossRefPubMed Cheng CH, Huang CC, Leu ML et al (1997) Hepatitis B vaccine in hemodialysis patients with hepatitis C infection. Vaccine 15:1353–1357CrossRefPubMed
5.
Zurück zum Zitat Al Saran K, Sabry A, Al Halawany Z et al (2014) Factors affecting response to hepatitis B vaccine among hemodialysis patients in a large Saudi Hemodialysis Center. Saudi J Kidney Dis Transpl 25:185–191CrossRefPubMed Al Saran K, Sabry A, Al Halawany Z et al (2014) Factors affecting response to hepatitis B vaccine among hemodialysis patients in a large Saudi Hemodialysis Center. Saudi J Kidney Dis Transpl 25:185–191CrossRefPubMed
6.
7.
Zurück zum Zitat CDC (2001) Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 50:1–43 CDC (2001) Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 50:1–43
8.
Zurück zum Zitat Rodby RA, Trenholme GM (1991) Vaccination of the dialysis patient. Semin Dial 4:102–105CrossRef Rodby RA, Trenholme GM (1991) Vaccination of the dialysis patient. Semin Dial 4:102–105CrossRef
9.
Zurück zum Zitat Dinits-Pensy M, Forrest GN, Cross AS et al (2005) The use of vaccines in adult patients with renal disease. Am J Kidney Dis 46:997–1011CrossRefPubMed Dinits-Pensy M, Forrest GN, Cross AS et al (2005) The use of vaccines in adult patients with renal disease. Am J Kidney Dis 46:997–1011CrossRefPubMed
10.
Zurück zum Zitat Sheth RD, Peskin MF, Du XL (2014) The duration of hepatitis B vaccine immunity in pediatric dialysis patients. Pediatr Nephrol 10:2029–2037CrossRef Sheth RD, Peskin MF, Du XL (2014) The duration of hepatitis B vaccine immunity in pediatric dialysis patients. Pediatr Nephrol 10:2029–2037CrossRef
11.
Zurück zum Zitat Tsouchnikas I, Dounousi E, Xanthopoulou K et al (2007) Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination. Clin Nephrol 68:228–234CrossRefPubMed Tsouchnikas I, Dounousi E, Xanthopoulou K et al (2007) Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination. Clin Nephrol 68:228–234CrossRefPubMed
12.
Zurück zum Zitat Kausz A, Pahari D (2004) The value of vaccination in chronic kidney disease. Semin Dial 17:9–11CrossRefPubMed Kausz A, Pahari D (2004) The value of vaccination in chronic kidney disease. Semin Dial 17:9–11CrossRefPubMed
13.
Zurück zum Zitat NKF-K/DOQI clinical practice guidelines for hemodialysis adequacy: update 2000. Am J Kidney Dis 37:S7–S64 (2001) NKF-K/DOQI clinical practice guidelines for hemodialysis adequacy: update 2000. Am J Kidney Dis 37:S7–S64 (2001)
14.
Zurück zum Zitat NKF-K/DOQI clinical practice guidelines for peritoneal dialysis adequacy: update 2000. Am J Kidney Dis 37:S65–S136 (2001) NKF-K/DOQI clinical practice guidelines for peritoneal dialysis adequacy: update 2000. Am J Kidney Dis 37:S65–S136 (2001)
15.
Zurück zum Zitat Lioussfi Z, Errami Z, Radoui A et al (2014) Viral hepatitis C and B among dialysis patients at the Rabat University Hospital: prevalence and risk factors. Saudi J Kidney Dis Transpl 25:672–679CrossRefPubMed Lioussfi Z, Errami Z, Radoui A et al (2014) Viral hepatitis C and B among dialysis patients at the Rabat University Hospital: prevalence and risk factors. Saudi J Kidney Dis Transpl 25:672–679CrossRefPubMed
16.
Zurück zum Zitat Kalantari H, Ebadi S, Yaran M et al (2014) Prevalence and risk factors of hepatitis B and C viruses among hemodialysis patients in Isfahan, Iran. Adv Biomed Res 27(3):73 Kalantari H, Ebadi S, Yaran M et al (2014) Prevalence and risk factors of hepatitis B and C viruses among hemodialysis patients in Isfahan, Iran. Adv Biomed Res 27(3):73
17.
Zurück zum Zitat Orasan OH, Sava M, Iancu M et al (2015) Serum hyaluronic acid in chronic viral hepatitis B and C: a biomarker for assessing liver fibrosis in chronic hemodialysis patients. Int Urol Nephrol 47(7):1209–1217CrossRefPubMed Orasan OH, Sava M, Iancu M et al (2015) Serum hyaluronic acid in chronic viral hepatitis B and C: a biomarker for assessing liver fibrosis in chronic hemodialysis patients. Int Urol Nephrol 47(7):1209–1217CrossRefPubMed
18.
Zurück zum Zitat Orasan OH, Iancu M, Sava M et al (2015) Non-invasive assessment of liver fibrosis in chronic viral hepatitis. Ren Fail 37(9):1531–1532CrossRefPubMed Orasan OH, Iancu M, Sava M et al (2015) Non-invasive assessment of liver fibrosis in chronic viral hepatitis. Ren Fail 37(9):1531–1532CrossRefPubMed
19.
Zurück zum Zitat Evirgen Ö, Önlen Y, Motor VK et al (2010) The evaluation of the seroprevalence of HBV and HCV infections in patients with hemodialysis in Hatay City and the assessment of antibody response to hepatitis B vaccination. Viral Hepat J 16(2):57–63 (Turkish) Evirgen Ö, Önlen Y, Motor VK et al (2010) The evaluation of the seroprevalence of HBV and HCV infections in patients with hemodialysis in Hatay City and the assessment of antibody response to hepatitis B vaccination. Viral Hepat J 16(2):57–63 (Turkish)
20.
Zurück zum Zitat Sayan M, Dogan C (2012) Genotype/subgenotype distribution of hepatitis B virus among hemodialysis patients with chronical hepatitis B. Ann Hepatol 11:849–854PubMed Sayan M, Dogan C (2012) Genotype/subgenotype distribution of hepatitis B virus among hemodialysis patients with chronical hepatitis B. Ann Hepatol 11:849–854PubMed
21.
Zurück zum Zitat Yakaryilmaz F, Gurbuz OA, Guliter S et al (2006) Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail 28:729–735CrossRefPubMed Yakaryilmaz F, Gurbuz OA, Guliter S et al (2006) Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail 28:729–735CrossRefPubMed
22.
Zurück zum Zitat Kao JH, Hsu HM, Shau WY et al (2001) Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 139:349–352CrossRefPubMed Kao JH, Hsu HM, Shau WY et al (2001) Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 139:349–352CrossRefPubMed
23.
Zurück zum Zitat Novarro JF, Teruel JL, Mateos ML et al (1996) Antibody level after hepatitis B vaccination in hemodialysis patients; influence of hepatitis C virus infection. Am J Nephrol 16:95–97CrossRef Novarro JF, Teruel JL, Mateos ML et al (1996) Antibody level after hepatitis B vaccination in hemodialysis patients; influence of hepatitis C virus infection. Am J Nephrol 16:95–97CrossRef
24.
Zurück zum Zitat Eleftheriadis T, Pissas G, Antoniadi G et al (2014) Factors affecting effectiveness of vaccination against hepatitis B virus in hemodialysis patients. World J Gastroenterol 20:12018–12025CrossRefPubMedPubMedCentral Eleftheriadis T, Pissas G, Antoniadi G et al (2014) Factors affecting effectiveness of vaccination against hepatitis B virus in hemodialysis patients. World J Gastroenterol 20:12018–12025CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Chaves SS, Daniels D, Cooper BW et al (2011) Immunogenicity of hepatitis B vaccine among hemodialysis patients: effect of revaccination of non-responders and duration of protection. Vaccine 29:9618–9623CrossRefPubMed Chaves SS, Daniels D, Cooper BW et al (2011) Immunogenicity of hepatitis B vaccine among hemodialysis patients: effect of revaccination of non-responders and duration of protection. Vaccine 29:9618–9623CrossRefPubMed
27.
Zurück zum Zitat Center for Disease Control and Prevention (2002) General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR 51:1–35 Center for Disease Control and Prevention (2002) General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR 51:1–35
28.
Zurück zum Zitat Pereira ZT, Mendoza-Sassi RA (2012) Factors associated with the immune response to hepatitis B vaccine in Brazilian hemodialysis patients. Rev Med Chile 140:882–888CrossRefPubMed Pereira ZT, Mendoza-Sassi RA (2012) Factors associated with the immune response to hepatitis B vaccine in Brazilian hemodialysis patients. Rev Med Chile 140:882–888CrossRefPubMed
29.
Zurück zum Zitat Fabrizi F, Martin P, Dixit V et al (2004) Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease. Aliment Pharmacol Ther 20:1053–1062CrossRefPubMed Fabrizi F, Martin P, Dixit V et al (2004) Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease. Aliment Pharmacol Ther 20:1053–1062CrossRefPubMed
30.
Zurück zum Zitat Sit D, Esen B, Atay AE et al (2015) Is hemodialysis a reason for unresponsiveness to hepatitis B vaccine? Hepatitis B virus and dialysis therapy. World J Hepatol 18:761–768CrossRef Sit D, Esen B, Atay AE et al (2015) Is hemodialysis a reason for unresponsiveness to hepatitis B vaccine? Hepatitis B virus and dialysis therapy. World J Hepatol 18:761–768CrossRef
31.
Zurück zum Zitat Liu YL, Kao MT, Huang CC (2005) A comparison of responsiveness to hepatitis B vaccination in patients on hemodialysis and peritoneal dialysis. Vaccine 23:3957–3960CrossRefPubMed Liu YL, Kao MT, Huang CC (2005) A comparison of responsiveness to hepatitis B vaccination in patients on hemodialysis and peritoneal dialysis. Vaccine 23:3957–3960CrossRefPubMed
32.
Zurück zum Zitat Dogukan A, Taskapan H, Guven M et al (1999) Responsiveness to hepatitis B vaccine in hemodialysis, CAPD, and predialysis patients by doubling the dose schedule. Turk Nephrol Dial Transpl 4:192–194 (Turkish) Dogukan A, Taskapan H, Guven M et al (1999) Responsiveness to hepatitis B vaccine in hemodialysis, CAPD, and predialysis patients by doubling the dose schedule. Turk Nephrol Dial Transpl 4:192–194 (Turkish)
33.
Zurück zum Zitat Morse CG, High KP (2015) Nutrition, immunity and infection. In: Bennet JE, Dolin R, Blaser MJ (eds) Principles and practice of infectious diseases. Elsevier, Sounders, Philadelphia, pp 125–133 Morse CG, High KP (2015) Nutrition, immunity and infection. In: Bennet JE, Dolin R, Blaser MJ (eds) Principles and practice of infectious diseases. Elsevier, Sounders, Philadelphia, pp 125–133
34.
Zurück zum Zitat Bandaru P, Rajkumar H, Nappanveettil G (2011) Altered or impaired immune response to hepatitis B vaccine in WNIN/GR-Ob rat: an obese rat model with impaired glucose tolerance. ISRN Endocrinol 2011:980105CrossRefPubMedPubMedCentral Bandaru P, Rajkumar H, Nappanveettil G (2011) Altered or impaired immune response to hepatitis B vaccine in WNIN/GR-Ob rat: an obese rat model with impaired glucose tolerance. ISRN Endocrinol 2011:980105CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Gunduz Z, Dusunsel R, Patıroglu T et al (1995) Hepatitis B vaccination and determination of immune response in chronic hemodialysis patients. Turk Nephrol Dial Transpl 1:25–32 (Turkish) Gunduz Z, Dusunsel R, Patıroglu T et al (1995) Hepatitis B vaccination and determination of immune response in chronic hemodialysis patients. Turk Nephrol Dial Transpl 1:25–32 (Turkish)
36.
Zurück zum Zitat Roozbeh J, Moini M, Lankarani KB et al (2005) Low dose intradermal versus high dose intramuscular hepatitis B vaccination in patients on chronic hemodialysis. ASAIO J 51:242–245CrossRefPubMed Roozbeh J, Moini M, Lankarani KB et al (2005) Low dose intradermal versus high dose intramuscular hepatitis B vaccination in patients on chronic hemodialysis. ASAIO J 51:242–245CrossRefPubMed
37.
Zurück zum Zitat Chin AI (2003) Hepatitis B virus vaccine response in hemodialysis: baseline patient characteristics. Hemodial Int 7:296–303CrossRefPubMed Chin AI (2003) Hepatitis B virus vaccine response in hemodialysis: baseline patient characteristics. Hemodial Int 7:296–303CrossRefPubMed
38.
Zurück zum Zitat Fabrizi F, Dixit V, Martin P, Messa P et al (2012) Erythropoietin use and immunogenicity of hepatitis B virus vaccine in chronic kidney disease patients: a meta-analysis. Kidney Blood Press Res 35(6):504–510CrossRefPubMed Fabrizi F, Dixit V, Martin P, Messa P et al (2012) Erythropoietin use and immunogenicity of hepatitis B virus vaccine in chronic kidney disease patients: a meta-analysis. Kidney Blood Press Res 35(6):504–510CrossRefPubMed
39.
Zurück zum Zitat Khan AN, Bernardini J, Rault RM et al (1996) Low seroconversion with hepatitis B vaccination in peritoneal dialysis patients. Perit Dial Int 16:370–373PubMed Khan AN, Bernardini J, Rault RM et al (1996) Low seroconversion with hepatitis B vaccination in peritoneal dialysis patients. Perit Dial Int 16:370–373PubMed
40.
Zurück zum Zitat Mitwalli A (1996) Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. Nephron 73:417–420PubMed Mitwalli A (1996) Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. Nephron 73:417–420PubMed
41.
Zurück zum Zitat Bel’eed K, Wright M, Eadington D et al (2002) Vaccination against hepatitis B infection in patients with end stage renal disease. Postgrad Med J 78:538–540CrossRefPubMedPubMedCentral Bel’eed K, Wright M, Eadington D et al (2002) Vaccination against hepatitis B infection in patients with end stage renal disease. Postgrad Med J 78:538–540CrossRefPubMedPubMedCentral
Metadaten
Titel
Factors affecting responsiveness to hepatitis B immunization in dialysis patients
verfasst von
Ali Asan
Huriye Demirhan
Hülya Çetin Sorkun
Sevgi Özkan
Mehtap Aydın
Davut Akın
Bengü Tatar
Binali Çatak
Alper Şener
Şükran Köse
Publikationsdatum
15.06.2017
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 10/2017
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-017-1616-9

Weitere Artikel der Ausgabe 10/2017

International Urology and Nephrology 10/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.